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Abstract
Background: After analysis of minor RAS mutations (KRAS exon 3, 4/NRAS) in the FIRE-3 and PRIME studies, an
expanded range of RAS mutations were established as a negative predictive marker for the efficacy of anti-EGFR
antibody treatment. BRAF and PIK3CA mutations may be candidate biomarkers for anti-EGFR targeted therapies.
However, it remains unknown whether RAS/PIK3CA/BRAF tumor mutations can predict the efficacy of bevacizumab
in metastatic colorectal cancer. We assessed whether selection according to RAS/PIK3CA/BRAF mutational status
could be beneficial for patients treated with bevacizumab as first-line treatment for metastatic colorectal cancer.
Methods: Of the 1001 consecutive colorectal cancer patients examined for RAS, PIK3CA, and BRAF tumor mutations
using a multiplex kit (Luminex®), we studied 90 patients who received combination chemotherapy with bevacizumab
as first-line treatment for metastatic colorectal cancer. The objective response rate (ORR) and progression-free survival
(PFS) were evaluated according to mutational status.
Results: The ORR was higher among patients with wild-type tumors (64.3%) compared to those with tumors that were
only wild type with respect to KRAS exon 2 (54.8%), and the differences in ORR between patients with wild-type and
mutant-type tumors were greater when considering only KRAS exon 2 mutations (6.8%) rather than RAS/PIK3CA/BRAF
mutations (18.4%). There were no statistically significant differences in ORR or PFS between all wild-type tumors and
tumors carrying any of the mutations. Multivariate analysis revealed that liver metastasis and RAS and BRAF mutations
were independent negative factors for disease progression after first-line treatment with bevacizumab.
Conclusions: Patient selection according to RAS/PIK3CA/BRAF mutations could help select patients who will achieve a
better response to bevacizumab treatment. We found no clinical benefit of restricting combination therapy with
bevacizumab for metastatic colorectal cancer patients with EGFR-wild type tumors.
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Background
The EGFR signaling pathway has a key role in the prolif-
eration and survival of colorectal cancer cells. Point
mutations in exon 2 of the KRAS gene have been shown
to be negative predictive markers of the response to
anti-EGFR treatment, and consequently anti-EGFR anti-
bodies were not administered to patients with KRAS
exon 2 mutant tumors [1]. After a retrospective analysis
of minor RAS mutations (e.g. KRAS exon 3 and 4/NRAS)
in the FIRE-3 and PRIME studies [2, 3], the so called “all
RAS mutation” also came to be regarded as a negative
biomarker for anti-EGFR antibody treatment [4]. In
addition to RAS, BRAF and PIK3CA mutations are
potential biomarkers of response to anti-EGFR targeted
therapies [5]. However, it remains unknown whether EGFR
pathway mutations affect the efficacy of bevacizumab
(Bmab) in metastatic colorectal cancer (mCRC). We eval-
uated the significance of RAS/PIK3CA/BRAF tumor mu-
tations in patients receiving combination chemotherapy
with Bmab as the first-line treatment for mCRC, and we
assessed whether these mutations could be used to select




This was a retrospective study conducted at a single
Japanese institute and approved by the ethics committee
of Cancer Institute Hospital of Japanese Foundation for
Cancer Research (No.2009-1048). Of the 1001 consecutive
patients with histologically confirmed CRC who were ex-
amined for tumor RAS, PIK3CA, and BRAF mutations in
our institute between November 2006 and December
2013, 90 patients were administered combination chemo-
therapy with Bmab as the first-line treatment for mCRC.
Patients who received neo-adjuvant chemotherapy (NAC)
or adjuvant chemotherapy completed less than 6 months
before enrollment to this study were excluded. Patients
who had undergone surgery for metastatic sites were in-
cluded if it had been performed more than 4 weeks earlier.
Patients were required to have adequate hematologic, hep-
atic, cardiac, and renal function. Their medical records
were reviewed to obtain data on clinicopathologic vari-
ables. All patients provided written informed consent
before receiving treatment.
Procedure
The treatment regimen was determined by the physician
for each patient. The following regimens were employed:
modified FOLFOX6 plus Bmab consisted of a fortnightly
course of Bmab (5 mg/kg intravenously over 30 to
90 min on day 1), oxaliplatin (85 mg/m2 intravenously
over 2 h on day 1) plus l-LV (200 mg/m2 intravenously
over 2 h on day 1) and 5-fluorouracil (5-FU) (400 mg/m2
bolus on day 1, followed by infusion of 2400 mg/m2 over
46 h); and CapeOX plus Bmab consisted of oxaliplatin
(130 mg/m2 intravenously over 2 h on day 1) plus oral
capecitabine (1000 mg/m2 twice daily for 2 weeks in a 3-
week cycle). Bmab (7.5 mg/kg) was administered ahead of
oxaliplatin intravenously on day 1 every 3 weeks. FOLFIRI
plus Bmab consisted of fortnightly courses of Bmab
(5 mg/kg intravenously over 30 to 90 min on day 1), iri-
notecan (150 mg/m2 intravenously over 2 h on day 1)
plus l-LV (200 mg/m2 intravenously over 2 h on day 1)
and 5-FU (400 mg/m2 bolus on day 1, followed by infu-
sion of 2400 mg/m2 over 46 h).
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) tumor tissue, which was mostly ob-
tained at biopsy. Mutations in KRAS codons 12 and 13
were examined using a kit based on a Luminex assay
(MEBGEN KRAS Mutation Detection kit, MBL). A
Luminex based kit (GENOSEARCH Mu-PACK, MBL)
was also used to detect a total of 36 mutations in KRAS
(codons 61 and 146), NRAS (codons 12, 13, and 61),
PIK3CA (codons 542, 545, 546, and 1047) and BRAF
(codon 600). The concordance of findings based on this
newly developed multiplex assay kit with conventional
direct sequencing results was confirmed previously [6].
Statistical analysis
The objective response rate (ORR) was evaluated according
to the Response Evaluation Criteria in Solid Tumors
(RECIST) ver. 1.1. The progression-free survival (PFS) and
overall survival (OS) were calculated using the Kaplan-
Meier method. PFS was defined as the duration of survival
from the start of chemotherapy to the date of recurrence or
death from any cause, whichever occurred first. Patients
with no recurrence until the cut-off date were regarded as
censored on the last date when no recurrence had been
proven by imaging. The disease-progression date was retro-
spectively re-analyzed by the investigator, and was defined
as the date on which progression was first detected
using a computed tomography (CT) or fluorodeoxyglucose-
positron emission tomography (FDG-PET) scan. If treat-
ments were discontinued before or continued after disease-
progression due to adverse events or the patient’s request,
they were censored at the time of the last radiological exam-
ination. OS was defined as survival from the start of chemo-
therapy to death from any cause. For patients who were lost
to follow-up, data were censored on the date when the pa-
tient was last known to be alive. The data cut-off date was
August 12, 2015. A one-sided Fisher’s exact test was used to
assess the statistical significance of the difference between
ORRs according to mutational status at a significance level
of 2.5%. Both PFS and OS were estimated using the Kaplan-
Meier method and compared using the log-rank test at a
significance level of 5%. In addition to RAS, PIK3CA, and
BRAF tumor mutations, variables with a P value less than
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0.05 in a univariate analysis were included in a multivariate
Cox regression analysis. All analyses were performed with
EZR (Saitama Medical Center, Jichi Medical University,
Saitama, Japan), which is a graphical user interface for R
software (The R Foundation for Statistical Computing) [7].
Results
Baseline characteristics
The baseline characteristics of the patients are shown in
Table 1. Their median age was 63 years (range, 27–79 years).
Forty-eight patients (53.3%) were men and 42 patients
(46.7%) were women. Almost all of the subjects had a good
performance status. Seventy-four patients (82.2%) had
colon cancer and 16 (17.8%) had rectal cancer, including
right-sided colon cancer (RCC) in 34 patients (37.8%) and
left-sided colorectal cancer (LCRC) in 56 patients (62.2%).
RCC was defined as a tumor arising from the cecum to the
transverse colon, excluding the appendix, while LCRC was
defined as a tumor arising from the descending colon to
the rectum. Of these 90 patients, the tumors of 43 patients
(46.7%) were found to have a mutation in KRAS exon 2. In
total 48 patients (53.3%) had a RAS mutation (KRAS/
NRAS). Seven patients (8.9%) had a PIK3CA mutation, and
another 7 (8.9%) had a BRAF mutation. Thirty-three pa-
tients (36.7%) had tumors with no RAS, PIK3CA, or BRAF
mutation.
Treatment exposure
Almost all patients received an oxaliplatin-containing
regimen, which was FOLFOX in 34 cases (37.8%) and
XELOX in 52 cases (57.8%). Among them, 13 (14.4%)
had been administered oxaliplatin prior to this treatment
as an adjuvant therapy. The primary tumor was resected
in 67 patients (74.4%) and 13 patients (14.4%) underwent
a metastatectomy.
ORR, PFS, and OS
The median follow-up period for all eligible patients was
23.5 (0.8–41.4) months, and 51 patients (56.7%) died by
the cut-off date. Seventy-seven of the 90 patients had
measurable lesions. The overall ORR was 52.6% whilst
the ORR of patients with no detected tumor mutations
was 64.3%. The ORRs of patients with a PIK3CA or





Median age (range), years 63 (27–79)
ECOG performance status
0 82 (91.1)
1, 2 8 (8.9)
Site of primary tumor
RCC (cecum to the transverse colon) 34 (37.8)















≥ 2 53 (58.9)
Chemotherapy regimen





Resection of primary tumor
Yes 67 (74.4)
No 23 (25.6)
Previous oxaliplatin treatment as adjuvant CTx
Yes 13 (14.4)
No 77 (85.6)













ECOG Eastern Cooperative Oncology Group, RCC right-sided colon cancer, LCRC
left-sided colorectal cancer, CTx chemotherapy
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BRAF tumor mutation were very low (28.6%), and more
than 40% of patients with a BRAF tumor mutation had
confirmed disease progression at the first evaluation
(Fig. 1). Although the ORR varied according to the mu-
tational status of the tumor, these differences were not
statistically significant (Table 2). The differences in ORR
became gradually greater among patients with wild-type
tumors as restricting treatment subjects from only wild
type with respect to KRAS exon 2, all RAS wild-type to-
ward all wild-type (RAS/PIK3CA/BRAF). The difference
in ORR between the whole population and patients with
all wild-type tumors was 11.7% (Fig. 2).
The overall median OS and PFS were 27.7 and
13.3 months, respectively. The ORR of patients with
KRAS exon 2 wild-type and mutant-type tumors differed
by 6.2%, and these populations had nearly identical
Kaplan-Meier curves for PFS (Fig. 3). The difference be-
tween ORRs (18.4%) was larger when comparing patients
with wild-type tumors to those with a tumor carrying any
mutation. There was no statistically significant difference
in PFS between these groups, although there was a slightly
larger difference in Kaplan-Meier curves (Fig. 3).
Univariate analysis revealed that an elevated serum C-
reactive protein (CRP) level (>0.05 mg/dl), an unresect-
able primary tumor, and liver metastases were associated
with a significantly shorter PFS (Table 3). Multivariate
analysis that included RAS, PIK3CA, and BRAF tumor
mutations and baseline prognostic variables revealed
that liver metastasis, unresectable primary tumor, RAS
and BRAF tumor mutations had independent prognostic
value for early progression (Table 3).
Discussion
In clinical practice, it is often not as easy to conduct CT
scans at regular intervals as it is in clinical trials. We
considered that the ORR would be a relatively rigid par-
ameter for evaluating the efficacy of first-line treatment
in clinical practice. In this study, treatment was discon-
tinued due to not only disease progression, but also adverse
events or patient refusal, and 21 patients discontinued
treatment before disease progression was confirmed by im-
aging. Time to treatment failure (TTF) is sometimes chosen
as an endpoint instead of PFS in clinical trials. However, we
considered that PFS would be a more suitable endpoint to
evaluate the biological activity of the tumor and drug resist-
ance compared to TTF. OS was the most rigid endpoint
but would be determined by not only the first-line treat-
ment but also by second-line and subsequent treatments.
The difference in OS may be a result of anti-EGFR
therapy after the first-line treatment in patients who
have KRAS or RAS wild-type tumors. We therefore
assessed the relationship between clinicopathologic fac-
tors including RAS, PIK3CA, and BRAF tumor muta-
tion status and PFS.
In this study, we found that patients with a RAS, PIK3CA,
or BRAF tumor mutation had a lower ORR than patients
with tumors that did not carry these mutations, although
this difference was not statistically significant. Patient selec-
tion according to tumor mutations in the EGFR pathway
might improve the overall response to combination therapy
with Bmab as a first-line treatment for mCRC. However,
these differences in ORRs could not translate into an
improved PFS. Multivariate analysis revealed a negative
predictive value of RAS and BRAF tumor mutations
with respect to first-line Bmab treatment. In this study,
all patients were treated with Bmab, and hence, we could
not clarify whether these gene mutations had predictive or
prognostic value.
Data from preclinical research has indicated that changes
in the EGFR signaling pathway might be related to the
efficacy of anti-VEGF therapy [8]. Post-analysis of the
AVF2107g trial revealed that adding Bmab to cytotoxic
chemotherapy was beneficial regardless of KRAS exon 2
mutation status [9]. KRAS exon 2 mutations are not
Fig. 1 Response according to tumor mutation status
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regarded as predictive markers of Bmab treatment.
However, we found that the ORR, PFS, and OS differed
between patients with KRAS wild-type and mutant
tumors (ORR, 60.0% vs. 41.2%; PFS, 13.5 months vs.
9.3 months; OS, 27.7 months vs. 19.9 months). These
findings are mostly similar to those of other trials com-
paring clinical outcomes between patients with KRAS
exon 2 wild-type and mutant tumors [10–12]. Although
statistically significant differences in OS and PFS
between patients with KRAS exon 2 wild-type and
mutant-type tumors were only shown in the MACRO
trial [12], there were numerical differences shown all
other trials. KRAS exon 2 wild-type tumors may predict
a favorable prognosis. In a retrospective analysis of the
PEAK, FIRE-3, and CALGB/SWOG80405 trials, this
trend was also apparent when including subjects with
any RAS tumor mutation, rather than just those with
KRAS exon 2 tumor mutations [13–15]. A recent retro-
spective analysis of data from the TRIBE trial suggested
that tumor mutations in both BRAF and RAS genes
predicted a poor outcome for patients undergoing first-
line treatment with Bmab plus FOLFIRI or FOLFOX-
IRI, although RAS mutations had less impact than
BRAF mutations [16]. Larger patient numbers would be
needed to translate the difference in ORR between
patients with wild-type and mutant tumors into an
improved clinical outcome, which may be why only the
MACRO trial, with the largest number of patients, re-
vealed statistically significant differences in outcome
between patients with KRAS wild-type and mutant-type
tumors.
Mutations in the BRAF gene have been shown to be
markers of a poor prognosis following mCRC treatment
[17, 18] and have a stronger prognostic value than RAS
mutations [19]. However, BRAF mutant cases were very
rare, only 8 in this cohort. It is therefore very difficult to
obtain an adequate number of these cases to show statis-
tically significant differences.
Taking into account these previous data, RAS and
BRAF mutations may be associated with the inferior effi-
cacy of Bmab treatment. However, due to the relatively
small effect of RAS mutations and the rarity of BRAF
mutations, we were unable to show statistically signifi-
cant differences in the ORR and PFS of patients under-
going first-line treatment with Bmab for mCRC.
The ORR and PFS in patients with any of the examined
mutations were 45.9% and 10.8 months, respectively, in
this study. These were comparable with those of patients
with KRAS exon 2 mutant tumors treated using FOLFOX4
alone in the OPUS study (ORR, 52.0%; PFS, 8.6 months)
[20]. However, in the cetuximab arm of the OPUS and
CRYSTAL trials, the ORR and PFS of patients with KRAS








All wt vs. any mt
Responder (n) 23 vs. 17 21 vs. 19 38 vs. 2 18 vs. 22
Non-responder (n) 19 vs. 18 15 vs. 21 31 vs. 5 10 vs. 26
ORR (%) 54.8 vs. 48.6 58.4 vs. 47.5 55.1 vs. 28.6 64.3 vs. 45.9
Difference in ORR 6.8 10.9 26.5 18.4
P value* 0.651 0.368 0.246 0.155
Responder, CR + PR; Non-responder, SD + PD + NE; ORR, overall response rate; wt, wild-type; mt, mutant
*calculated using Fisher’s exact test
Fig. 2 Responses among patients with wild-type tumor KRAS exon 2, RAS, and RAS/PIK3CA/BRAF
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mutant tumors were much worse (ORR, 26.0 and 31.3%
respectively; PFS, 5.5 and 7.4 months, respectively) than
patients with no tumor mutations in our study [20, 21].
Our study did not show that mCRC patients with a tumor
mutation in RAS, PIK3CA, or BRAF had a poorer re-
sponse to combination chemotherapy with Bmab com-
pared with patients who had none of these mutations. As
such, there are insufficient data to justify the exclusion of
patients with a RAS, PIK3CA, or BRAF tumor mutation
from Bmab treatment regimens.
Our study has several limitations. Firstly, this was
retrospective cohort study conducted at a single insti-
tute. Secondly, there was selection bias in the treatment
of patients with KRAS wild-type tumors, especially those
who had metastases only in the liver. In our institute,
patients with KRAS wild-type tumors and liver only
metastases were administered anti-EGFR therapy as an
initial standard treatment in order to achieve conver-
sion to metastatectomy. Patients with KRAS wild-type
tumors and liver metastases in this cohort had relatively
unfavorable factors, such as a high tumor burden or mul-
tiple organ metastases, and patients with relatively favor-
able factors were usually excluded. This may explain why
liver metastasis was an independent predictor of a poor
prognosis in this cohort. Patients with RAS wild-type tu-
mors in this cohort might have had a poor prognosis,
Fig. 3 Relationship between overall response rate (ORR) and progression free survival (PFS) in patients with wild-type or mutant (a) KRAS exon 2
and (b) RAS/PIK3CA/BRAF tumors
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compared to those included in other studies, and this se-
lection bias might have affected the outcome of patients
with tumors that do not carry mutations in the genes
studied here. Thirdly, due to the rare incidence of PIK3CA
and BRAF mutation in CRC, we could evaluate only small
number patients with these mutations.
Table 3 Univariate and multivariate analysis of pr4gression-free survival (PFS) (n = 90)
Variable Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Sex
Male vs. female 1.0 vs. 0.72 (0.42–1.24) 0.236
Age
< 63 y.o vs. ≥63 y.o 1.0 vs. 0.82 (0.48–1.40) 0.472
ECOG PS
0 vs. 1,2 1.0 vs. 0.66 (0.21–2.14) 0.490
Site of primary tumor
RCC vs. LCRC 1.0 vs. 0.88 (0.51–1.52) 0.643
Differentiated-type
yes vs. no 1.0 vs. 1.78 (0.75–4.22) 0.188
Synchronous mets
yes vs. no 1.0 vs. 0.61 (0.29–1.30) 0.201
Sites of metastasis
Non-liver vs. liver 1.0 vs. 1.84 (1.06–3.20) 0.031 1.0 vs. 3.26 (1.57–6.77) 0.002
Non-lung vs. lung 1.0 vs. 1.17 (0.68–2.00) 0.567
Non-LN vs. LN 1.0 vs. 0.67 (0.37–1.20) 0.177
Non-P vs. P 1.0 vs. 0.95 (0.51–1.78) 0.878
Number of metastases
1 vs. ≥2 1.0 vs. 0.87 (0.51–1.50) 0.628
Primary resection
yes vs. no 1.0 vs. 2.00 (1.09–3.66) 0.024 1.0 vs. 2.13 (1.05–4.29) 0.035
Prior L-OHP
yes vs. no 1.0 vs. 0.75 (0.35–1.60) 0.457
ALP (/)
≤ ULN vs. >ULN 1.0 vs. 1.07 (0.56–2.04) 0.836
LDH (/IU)
≤ ULN vs. >ULN 1.0 vs. 1.27 (0.74–2.21) 0.387
CRP (mg/dl)
≤ ULN vs. >ULN 1.0 vs. 2.35 (1.32–4.17) <0.001 1.0 vs. 1.57 (0.79–3.10) 0.196
CEA
≤ ULN vs. >ULN 1.0 vs. 0.90 (0.49–1.65) 0.735
CA19-9
≤ ULN vs. >ULN 1.0 vs. 1.63 (0.95–2.80) 0.076
RAS status
Wild-type vs. mutant 1.0 vs. 1.36 (0.79–2.32) 0.264 1.0 vs. 2.01 (1.07–3.76) 0.030
PIK3CA status
Wild-type vs. mutant 1.0 vs. 1.00 (0.36–2.77) 0.993 1.0 vs. 0.66 (0.21–2.03) 0.466
BRAF status
Wild-type vs. mutant 1.0 vs. 1.60 (0.68–3.75) 0.285 1.0 vs. 3.87 (1.38–10.9) 0.010
CI confidence interval, HR hazard ratio, RCC right-sided colon cancer, LCRC left-sided colorectal cancer, mets metastasis, LN lymph node, P peritoneum, ULN upper
limit of normal, NA not assessable. All data in italics are with p-value <0.05
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Conclusion
There were no statistically significant differences in ORR
and PFS according to mutations in EGFR pathway genes
in patients receiving cytotoxic chemotherapy with Bmab
as the first-line treatment for mCRC. RAS/PIK3CA/
BRAF mutations could help identify tumors that will re-
spond to both anti-EGFR antibodies and Bmab. How-
ever, this study did not find a clinical benefit for
restricting Bmab treatment to mCRC patients with tu-
mors that have wild-type EGFR pathway genes.
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